SCHEMBL3092800

SCHEMBL3092800

CCOC(=O)C(Cc1ccc(OC(F)(F)F)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 3/20 0.49
LARS1 Q9P2J5 1/20 0.47
POLB P06746 1/20 0.46
MMP8 P22894 1/20 0.45
PPARG P37231 3/20 0.44
PPARA Q07869 3/20 0.44
EPHX2 P34913 1/20 0.44
GAA P10253 1/20 0.43
RAPGEF3 O95398 1/20 0.43
F2 P00734 2/20 0.43
PPARD Q03181 2/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.41
BACE1 P56817 1/20 0.41
MMP1 P03956 1/20 0.41
MMP9 P14780 1/20 0.41
MMP13 P45452 1/20 0.41
ADAM17 P78536 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093149 0.89 KAT6A (0.53) KAT6ALARS1POLBPPARGPPARA
SCHEMBL3093170 0.88 ALDH1A1 (0.54) LARS1POLBMMP8PPARGPPARA
SCHEMBL3093748 0.88 LARS1 (0.54) KAT6ALARS1POLBMMP8GAA
SCHEMBL3091388 0.88 MMP8 (0.58) KAT6ALARS1POLBMMP8PPARG
SCHEMBL14999934 0.87 KAT6A (0.48) KAT6ALARS1POLBPPARGPPARA
SCHEMBL3100450 0.86 LARS1 (0.53) KAT6ALARS1POLBMMP8PPARG
SCHEMBL3097275 0.86 MMP8 (0.51) KAT6ALARS1POLBMMP8PPARG
SCHEMBL3097004 0.84 LARS1 (0.50) KAT6ALARS1POLBMMP8GAA
SCHEMBL3086139 0.84 KAT6A (0.45) KAT6ALARS1POLBPPARGPPARA
SCHEMBL3085503 0.83 LARS1 (0.47) LARS1POLBMMP8GAARAPGEF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 KAT6A 3337/4885LARS1 1976/4885POLB 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.